Personalized mRNA Vaccine Marks a New Chapter in Melanoma Treatment

Positive phase 3 findings for an individualized mRNA-based neoantigen therapy could signal a shift toward more personalized adjuvant treatment for patients with resectable melanoma.

Goran Mićević, MD, PhD, assistant professor of dermatology and pathology at Yale University and a member of the Center for Molecular and Cellular Oncology, joined Dermatology Times Editor in Chief Christopher Bunick, MD, PhD, to discuss findings from the phase 3 INTerpath-001 trial (NCT05933577) evaluating individualized neoantigen therapy in combination with immune checkpoint blockade.

The trial evaluated intismeran autogene, an individualized neoantigen therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with completely resected stage IIB to IV melanoma. The combination met the trial's primary end point of recurrence-free survival (RFS) and key secondary end point of distant metastasis-free survival (DMFS).

Mićević called the findings an important development for patients while emphasizing that they also open new questions about how individualized neoantigen therapies could ultimately fit into melanoma treatment.

How an Individualized Neoantigen Therapy Is Made

Neoantigens arise from genetic changes unique to a patient's tumor, including point mutations, frameshifts, and splice-site changes. Because these alterations are not present in normal somatic cells, some can produce peptides recognizable by the immune system.

The individualized vaccine approach uses tumor tissue and blood samples followed by high-resolution sequencing to identify tumor-specific neoantigens that may elicit an antitumor immune response. Selected neoantigens are then incorporated into an individualized mRNA therapy and administered intramuscularly.

It is a genetic change in the tumor that's unique to the tumor, — Mićević

According to Mićević, the ability to tailor treatment to the molecular characteristics of an individual patient's melanoma represents an important advance in personalized cancer therapy.

“This is a pivotal trial, first of its kind, where a completely individualized neoantigen is being used in the therapy of a patient,” he said.

Phase 3 Trial Meets RFS and DMFS End Points

The phase 3 INTerpath-001 trial demonstrated significant improvements in both RFS and DMFS with individualized neoantigen therapy plus checkpoint blockade compared with checkpoint blockade alone.

Mićević noted that the findings are consistent with the benefit previously observed in phase 2b research, in which the combination demonstrated an approximately 50% reduction in the risk of recurrence or death with longer-term follow-up.

Beyond the numerical findings, Mićević emphasized the practical significance of extending the amount of time patients live without recurrent disease.

Disease-free survival is very meaningful clinically. It means time that you're not spending in the hospital, time that you're spending outside with your family and enjoying life, pursuing things that matter to you, — Goran Mićević, MD, PhD,

Although overall survival data remain immature, Mićević said continued follow-up will be important in determining whether the improvements in disease control ultimately translate into an overall survival benefit.

Where the Vaccine Could Fit Into Melanoma Treatment

The phase 3 trial included patients with stage IIB through stage IV resectable melanoma who had undergone complete surgical resection. Mićević stressed that the approach therefore does not eliminate the role of surgery in eligible patients.

“The population for the trial was stage IIb through stage IV resectable melanoma,” he said.

How the therapy ultimately fits into the melanoma treatment paradigm remains an open question, particularly as neoadjuvant treatment becomes increasingly important.

One practical limitation is manufacturing time. Mićević said developing the personalized vaccine currently takes approximately 6 to 8 weeks, which may make incorporating it before surgery difficult. For now, he sees a clearer potential role in the adjuvant setting.

“I think it's a really, really valuable addition, and definitely a new chapter, I would say, in melanoma therapy and cancer therapy altogether,” Mićević said.

He added that continued optimization of manufacturing and treatment workflows could eventually change where the therapy is incorporated.

HLA Independence May Broaden Applicability

Mićević also highlighted correlative findings suggesting the treatment effect is independent of HLA type, tumor mutational burden, and PD-L1 expression.

HLA independence is particularly noteworthy because HLA molecules play an important role in presenting neoantigens to the immune system. Requiring a specific HLA allele could substantially restrict the population eligible for a neoantigen-directed therapy.

“It's HLA-independent, which speaks to the broad potential applicability of this,” Mićević said.

According to Mićević, the findings suggest the approach could potentially be applicable across a broader group of patients rather than being restricted to those with a particular HLA type.

The implications may also extend beyond melanoma. Individualized neoantigen therapies are being investigated in other malignancies, and Mićević pointed to research in pancreatic, bladder, and lung cancers as evidence of the platform's broader potential.

What Comes Next for Individualized Cancer Vaccines

Despite the positive phase 3 findings, Mićević characterized the results as the beginning rather than the culmination of individualized neoantigen therapy.

Future research will need to improve how clinically meaningful neoantigens are identified and determine which tumor mutations are actionable targets rather than passenger mutations that do not meaningfully contribute to an antitumor immune response.

Developing assays and biomarkers capable of making that distinction could further refine patient-specific vaccine design and potentially improve outcomes.

“I'd advise colleagues to keep an eye on this field,” Mićević said. “It's rapidly developing.”

For dermatologists involved in melanoma care, the phase 3 findings provide early evidence that individualized mRNA-based treatment may eventually become another component of the adjuvant melanoma treatment landscape—while raising new questions about patient selection, sequencing, manufacturing, and integration with existing immunotherapy.

References

1. Merck & Co., Inc., Moderna, Inc. Merck and Moderna announce phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met endpoints of recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with completely resected stage IIB-IV melanoma. Published August 19, 2026. Accessed August 20, 2026. Merck phase 3 INTerpath-001 announcement
2. Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632-644. doi:10.1016/S0140-6736(23)02268-7. https://pubmed.ncbi.nlm.nih.gov/38246194/
3. Moderna, Inc., Merck & Co., Inc. Moderna and Merck present 5-year data for intismeran autogene in combination with KEYTRUDA (pembrolizumab) in patients with high-risk stage III/IV melanoma following complete resection at the 2026 ASCO Annual Meeting. Published June 1, 2026. Accessed August 20, 2026. https://www.merck.com/news/moderna-and-merck-present-5-year-data-for-intismeran-autogene-in-combination-with-keytruda-pembrolizumab-in-patients-with-high-risk-stage-iii-iv-melanoma-following-complete-resection-at-the-20/